New drug combo shows promise for Hard-to-Treat cancers

NCT ID NCT05605509

Completed Disease control Sponsor: Canadian Cancer Trials Group Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called RP-6306 in 28 people with advanced cancer that could not be cured. The goal was to see if adding RP-6306 to standard treatment helps shrink tumors and is safe. Researchers also looked for specific biomarkers to see if some patients respond better.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer endometrial serous adenocarcinoma fallopian tube carcinoma ovarian carcinosarcoma ovarian serous adenocarcinoma primary peritoneal carcinoma triple-negative breast carcinoma uterine carcinosarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER

Contacts and locations

Locations

BCCA - Kelowna

Kelowna, British Columbia, V1Y 5L3, Canada
BCCA - Vancouver

Vancouver, British Columbia, V5Z 4E6, Canada
Kingston Health Sciences Centre

Kingston, Ontario, K7L 2V7, Canada
London Health Sciences Centre Research Inc.

London, Ontario, N6A 5W9, Canada
Ottawa Hospital Research Institute

Ottawa, Ontario, K1H 8L6, Canada
University Health Network

Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.